Sleep apnea syndrome in Japan: analysis of pathophysiology and nasal continuous positive airway pressure effectiveness

Forty eight Japanese sleep apnea syndrome (SAS) patients, whose apnea-hypopnea index (AHI) was more than 30 times/hr. from 5 university hospitals (46 males, 2 females) were enrolled in this study to analyze the characteristics of the disorder and the effectiveness of nasal continuous positive airway...

Full description

Saved in:
Bibliographic Details
Published inNihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society Vol. 36; no. 1; p. 53
Main Authors Takasaki, Y, Ohta, Y, Nishimura, M, Kawakami, Y, Kimura, H, Kuriyama, T, Akashiba, T, Horie, T, Ohi, M, Kuno, K
Format Journal Article
LanguageJapanese
Published Japan 01.01.1998
Subjects
Adult
Aged
Female
Glucose Intolerance - etiology
Humans
Hypertension - etiology
Male
Middle Aged
Positive-Pressure Respiration - methods
Severity of Illness Index
Sleep Apnea Syndromes - complications
Sleep Apnea Syndromes - physiopathology
Sleep Apnea Syndromes - therapy
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:Forty eight Japanese sleep apnea syndrome (SAS) patients, whose apnea-hypopnea index (AHI) was more than 30 times/hr. from 5 university hospitals (46 males, 2 females) were enrolled in this study to analyze the characteristics of the disorder and the effectiveness of nasal continuous positive airway pressure (nCPAP) effectiveness. Although the severity of excessive daytime sleepiness (EDS), depressive state, and ventricular premature beats caused by SAS seemed milder in Japanese than reported Caucasian patients, the prevalences of hypertension and glucose intolerance were quite high: 50 and 30% respectively. Treatment with nCPAP for 3 months was completed in 41 of 48 enrollees, a compliance rate of 85.4%, which was substantially higher than studies from Western countries. nCPAP treatment normalized about 50% of hypertensive patients and more than half of glucose intolerant patients. Moreover, EDS, driving ability, the severity of arrhythmia, and so forth were all improved with nCPAP. We, therefore, conclude that 1) SAS could differ between Japanese Caucasians in terms of clinical features resulting from SAS and 2) treatment with nCPAP is effective and should be considered as first-line treatment for patients with moderate to severe SAS, as reported in Western countries.
ISSN:1343-3490